Home LiteratureArticle Details
PMID: 20831903 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma.

Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, Kim B, Roberts LR

Abstract

There are few data available about the prevalence or effects of cirrhosis in patients with hepatocellular carcinoma (HCC) from viral hepatitis. We compared patients with HCC and hepatitis B virus (HBV) or hepatitis C virus (HCV) infections to determine the proportions of cirrhosis in each group, virologic and tumor characteristics, and overall survival. This analysis included patients with HBV (n = 64) or HCV (n = 118) infection who were diagnosed with HCC at the Mayo Clinic in Rochester, Minnesota from 1994-2008; groups were matched for age and sex. The diagnosis of cirrhosis was based on histology and, if histologic information was insufficient or unavailable, clinical indicators that included ascites or varices, thrombocytopenia or splenomegaly, and radiographic configuration of cirrhosis. Virologic characteristics, tumor stage, and patient survival were also assessed. The prevalence of histologic cirrhosis was 88% among patients with HBV infection and 93% among those with HCV infection (P = .46). When the most inclusive criteria for cirrhosis were applied, cirrhosis was present in 94% of patients with HBV and 97% with HCV (P = .24). Among HCV patients, 5.2% were negative for HCV RNA after antiviral treatment; 63.4% of HBV patients had HBV DNA <2000 IU/mL with or without treatment. Patients with HBV tended to have less surveillance and more advanced stages of HCC, without differences in survival from those with HCV infection (P = .75). Most patients with HCC and chronic viral hepatitis had evidence of cirrhosis, including those with HBV infection and those without active viral replication.

MeSH Terms
Aged Ascites/diagnosis Carcinoma, Hepatocellular/complications,pathology Esophageal and Gastric Varices/diagnosis Female Fibrosis/epidemiology,pathology Hepatitis B, Chronic/complications,pathology Hepatitis C, Chronic/complications,pathology Histocytochemistry Humans Male Middle Aged Minnesota/epidemiology Prevalence Splenomegaly/diagnosis Thrombocytopenia/diagnosis
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Yang Ju Dong
Mayo Clinic College of Medicine, Rochester, MN, USA.
Kim W Ray
Coelho Ritika
Mettler Teresa A
Benson Joanne T
Sanderson Schuyler O
Therneau Terry M
Kim Bohyun
Roberts Lewis R
References (31)
31 references, click to expand
  1. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases.
    Hepatology. 2000 Aug;32(2):200-4 PMID: 10915724
  2. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma.
    J Gastrointest Surg. 2004 Nov;8(7):794-804; discussion 804-5 PMID: 15531232
  3. Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis.
    Ann Hepatol. 2009 Jan-Mar;8(1):64-7 PMID: 19221537
  4. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.
    Hepatology. 1999 Mar;29(3):971-5 PMID: 10051505
  5. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.
    J Hepatol. 2001 Apr;34(4):593-602 PMID: 11394661
  6. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.
    Lancet. 2001 Jan 20;357(9251):196-7 PMID: 11213099
  7. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.
    Oncogene. 2003 Jun 19;22(25):3911-6 PMID: 12813464
  8. Surgical results in patients with hepatitis virus-related hepatocellular carcinoma in Taiwan.
    World J Surg. 2002 Jun;26(6):742-7 PMID: 12053231
  9. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
    JAMA. 2006 Jan 4;295(1):65-73 PMID: 16391218
  10. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
    Gastroenterology. 2010 May;138(5):1747-54 PMID: 20114048
  11. The role of cytokines in hepatocellular carcinoma.
    J Leukoc Biol. 2006 Dec;80(6):1197-213 PMID: 16946019
  12. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma.
    Hepatology. 2006 May;43(5):891-902 PMID: 16628664
  13. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma.
    J Hepatol. 2005 May;42(5):760-77 PMID: 15826727
  14. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Antivir Ther. 2007;12(8):1295-303 PMID: 18240869
  15. Hepadnaviral X Protein:Review of Recent Progress.
    J Biomed Sci. 1996 Jan;3(1):20-30 PMID: 11725079
  16. HCV-associated liver cancer without cirrhosis.
    Lancet. 1995 Feb 18;345(8947):413-5 PMID: 7772123
  17. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.
    Hepatology. 1995 Mar;21(3):650-5 PMID: 7875662
  18. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
    Hepatology. 2004 Mar;39(3):804-10 PMID: 14999700
  19. Prognosis of hepatocellular carcinoma: the BCLC staging classification.
    Semin Liver Dis. 1999;19(3):329-38 PMID: 10518312
  20. Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.
    Med Sci Monit. 2009 Jun;15(6):CR274-9 PMID: 19478697
  21. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.
    Gut. 2005 Nov;54(11):1610-4 PMID: 15871997
  22. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.
    Hepatology. 1999 Jun;29(6):1870-5 PMID: 10347132
  23. Hepatocellular carcinoma in Italian patients with cirrhosis.
    N Engl J Med. 1991 Sep 5;325(10):675-80 PMID: 1651452
  24. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
    J Hepatol. 2006 Oct;45(4):529-38 PMID: 16879891
  25. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients.
    Hepatol Res. 2005 Jul;32(3):173-84 PMID: 16024289
  26. Hepatocellular carcinoma: A global view.
    Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58 PMID: 20628345
  27. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan.
    Hepatology. 1995 Oct;22(4 Pt 1):1027-33 PMID: 7557847
  28. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators.
    Hepatology. 2000 Apr;31(4):840-5 PMID: 10733537
  29. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C.
    Hepatology. 1996 Aug;24(2):307-10 PMID: 8690397
  30. Management of hepatocellular carcinoma.
    Hepatology. 2005 Nov;42(5):1208-36 PMID: 16250051
  31. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.
    Cancer. 1985 Aug 15;56(4):918-28 PMID: 2990661
Article Info
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Abbr.
Clin Gastroenterol Hepatol
ISSN
1542-7714
Published
2011-01-00
Epub
2010-00-08
Pages
64-70
Language
English
Region
United States
NLM ID
101160775
PMCID
PMC3951426
Subset
IM
Grants
NIDDK NIH HHS · R01 DK034238 · United States
NIDDK NIH HHS · DK-34238 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]